<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2476436-A3" country="EP" doc-number="2476436" kind="A3" date="20140101" family-id="38626589" file-reference-id="318252" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146552986" ucid="EP-2476436-A3"><document-id><country>EP</country><doc-number>2476436</doc-number><kind>A3</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-11187013-A" is-representative="NO"><document-id mxw-id="PAPP154826909" load-source="docdb" format="epo"><country>EP</country><doc-number>11187013</doc-number><kind>A</kind><date>20070813</date><lang>EN</lang></document-id><document-id mxw-id="PAPP181744049" load-source="docdb" format="original"><country>EP</country><doc-number>11187013.5</doc-number><date>20070813</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140453835" ucid="EP-07801643-A" linkage-type="3" load-source="docdb"><document-id format="epo"><country>EP</country><doc-number>07801643</doc-number><kind>A</kind><date>20070813</date></document-id></priority-claim><priority-claim mxw-id="PPC140455372" ucid="GB-0615966-A" load-source="docdb"><document-id format="epo"><country>GB</country><doc-number>0615966</doc-number><kind>A</kind><date>20060811</date></document-id></priority-claim><priority-claim mxw-id="PPC140454168" ucid="GB-0710081-A" load-source="docdb"><document-id format="epo"><country>GB</country><doc-number>0710081</doc-number><kind>A</kind><date>20070525</date></document-id></priority-claim><priority-claim mxw-id="PPC140454021" ucid="GB-0711403-A" load-source="docdb"><document-id format="epo"><country>GB</country><doc-number>0711403</doc-number><kind>A</kind><date>20070613</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1620478425" load-source="docdb">A61K  35/17        20150101A I20180629RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988104676" load-source="docdb">C07K  14/47        20060101ALI20131122BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988114550" load-source="docdb">C07K  14/435       20060101ALI20131122BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988135898" load-source="docdb">A61K  39/35        20060101AFI20131122BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL-1919316350" load-source="docdb" scheme="CPC">C07K  14/62        20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919317022" load-source="docdb" scheme="CPC">C07K  14/415       20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919317278" load-source="docdb" scheme="CPC">C12Y 401/01015     20130101 LA20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919317532" load-source="docdb" scheme="CPC">C07K  14/4717      20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919319838" load-source="docdb" scheme="CPC">C12Y 111/01008     20130101 LA20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919320281" load-source="docdb" scheme="CPC">C12N   9/0065      20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919320716" load-source="docdb" scheme="CPC">A61K  39/0008      20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919321886" load-source="docdb" scheme="CPC">A61K2039/572       20130101 LA20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919323465" load-source="docdb" scheme="CPC">C07K  14/47        20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919323576" load-source="docdb" scheme="CPC">C07K2319/00        20130101 LA20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919324948" load-source="docdb" scheme="CPC">A61K  39/35        20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-1919325193" load-source="docdb" scheme="CPC">C12N   9/88        20130101 LI20160707BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2027192103" load-source="docdb" scheme="CPC">C07K  14/4713      20130101 FI20150825BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2027197449" load-source="docdb" scheme="CPC">A61K  35/17        20130101 LI20150825BHEP        </classification-cpc><classification-cpc mxw-id="PCL-2027197765" load-source="docdb" scheme="CPC">C07K  14/43531     20130101 LI20150825BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132191442" lang="DE" load-source="patent-office">Immunogene Peptide und deren Verwendung bei Immunerkrankungen</invention-title><invention-title mxw-id="PT132191443" lang="EN" load-source="patent-office">Immunogenic peptides and their use in immune disorders</invention-title><invention-title mxw-id="PT132191444" lang="FR" load-source="patent-office">Peptides immunogènes et leur utilisation dans les troubles immunitaires</invention-title><citations><patent-citations><patcit mxw-id="PCIT417548522" load-source="docdb" ucid="US-20030152581-A1"><document-id format="epo"><country>US</country><doc-number>20030152581</doc-number><kind>A1</kind><date>20030814</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT417549843" load-source="docdb" ucid="US-20050196386-A1"><document-id format="epo"><country>US</country><doc-number>20050196386</doc-number><kind>A1</kind><date>20050908</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT417554279" load-source="docdb" ucid="WO-2001070263-A1"><document-id format="epo"><country>WO</country><doc-number>2001070263</doc-number><kind>A1</kind><date>20010927</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit><patcit mxw-id="PCIT417556945" load-source="docdb" ucid="WO-2005039613-A1"><document-id format="epo"><country>WO</country><doc-number>2005039613</doc-number><kind>A1</kind><date>20050506</date></document-id><sources><source name="SEA" category="A" created-by-npl="N"/></sources></patcit></patent-citations><non-patent-citations><nplcit><text>ARUNACHALAM B ET AL: "Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT).", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 2, 18 January 2000 (2000-01-18), pages 745 - 750, XP002716244, ISSN: 0027-8424</text><sources><source mxw-id="PNPL59402249" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>BOLÍVAR J ET AL: "Molecular cloning of a zinc finger autoantigen transiently associated with interphase nucleolus and mitotic centromeres and midbodies. Orthologous proteins with nine CXXC motifs highly conserved from nematodes to humans.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 51, 17 December 1999 (1999-12-17), pages 36456 - 36464, XP002457888, ISSN: 0021-9258</text><sources><source mxw-id="PNPL59402250" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>CARLIER VINCENT A ET AL: "Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors.", PLOS ONE, vol. 7, no. 10, E45366, October 2012 (2012-10-01), pages 1 - 16, XP002716287, ISSN: 1932-6203</text><sources><source mxw-id="PNPL59402251" load-source="docdb" name="SEA" category="T"/></sources></nplcit><nplcit><text>FOMENKO DMITRI E ET AL: "Identity and functions of CxxC-derived motifs", BIOCHEMISTRY, vol. 42, no. 38, 30 September 2003 (2003-09-30), AMERICAN CHEMICAL SOCIETY, US, pages 11214 - 11225, XP002537801, ISSN: 0006-2960, DOI: 10.1021/BI034459S</text><sources><source mxw-id="PNPL59402252" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>GENTILE FABRIZIO ET AL: "Thyroglobulin as an autoantigen: what can we learn about immunopathogenicity from the correlation of antigenic properties with protein structure?", IMMUNOLOGY, vol. 112, no. 1, May 2004 (2004-05-01), pages 13 - 25, XP002716286, ISSN: 0019-2805</text><sources><source mxw-id="PNPL59402253" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>HAQUE M A ET AL: "Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition.", JOURNAL OF IMMUNOLOGY, vol. 166, no. 7, 1 April 2001 (2001-04-01), (BALTIMORE, MD. : 1950), pages 4543 - 4551, XP002716245, ISSN: 0022-1767</text><sources><source mxw-id="PNPL59402254" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>JANSSENS: "CD4 CD25 T Cells Lyse Antigen-Presenting B Cells by Fas-Fas Ligand Interaction in an Epitope-Specific Manner", THE JOURNAL OF IMMUNOLOGY, vol. 171, no. 9, 1 November 2003 (2003-11-01), pages 4604 - 4612, XP055047089, ISSN: 0022-1767</text><sources><source mxw-id="PNPL71459533" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>JENSEN P E: "Acidification and disulfide reduction can be sufficient to allow intact proteins to bind class II MHC.", JOURNAL OF IMMUNOLOGY, vol. 150, no. 8 Pt 1, 15 April 1993 (1993-04-15), (BALTIMORE, MD. : 1950), pages 3347 - 3356, XP002716243, ISSN: 0022-1767</text><sources><source mxw-id="PNPL59402256" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>KHARE MEENAKSHI ET AL: "HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis.", INTERNATIONAL IMMUNOLOGY, vol. 15, no. 4, April 2003 (2003-04-01), pages 535 - 546, XP002716284, ISSN: 0953-8178</text><sources><source mxw-id="PNPL59402257" load-source="docdb" name="SEA" category="X"/></sources></nplcit><nplcit><text>WEISSERT R ET AL: "MHC class II-regulated central nervous system autoaggression and T cell responses in peripheral lymphoid tissues are dissociated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.", JOURNAL OF IMMUNOLOGY, vol. 166, no. 12, 15 June 2001 (2001-06-15), (BALTIMORE, MD. : 1950), pages 7588 - 7599, XP002716285, ISSN: 0022-1767</text><sources><source mxw-id="PNPL59402258" load-source="docdb" name="SEA" category="X"/></sources></nplcit></non-patent-citations></citations></technical-data><related-documents><relation type="division"><child-doc ucid="EP-11187013-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>11187013</doc-number><kind>A</kind><date>20070813</date></document-id></child-doc><parent-doc ucid="EP-07801643.3"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>07801643.3</doc-number><date>20070813</date></document-id><parent-grant-document ucid="EP-2059256-B1"><document-id><country>EP</country><doc-number>2059256</doc-number><kind>B1</kind><date>20160803</date></document-id></parent-grant-document></parent-doc></relation><relation type="previously-filed-application"><child-doc ucid="EP-11187013-A"><document-id load-source="patent-office" format="epo"><country>EP</country><doc-number>11187013</doc-number><kind>A</kind><date>20070813</date></document-id></child-doc><parent-doc ucid="WO-PCT/EP2007/007165"><document-id load-source="patent-office" format="epo"><country>WO</country><doc-number>PCT/EP2007/007165</doc-number><date>20070813</date></document-id></parent-doc></relation></related-documents><parties><applicants><applicant mxw-id="PPAR918136844" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>LIFE SCIENCES RES PARTNERS VZW</last-name><address><country>BE</country></address></addressbook></applicant><applicant mxw-id="PPAR918170921" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>LIFE SCIENCES RESEARCH PARTNERS VZW</last-name></addressbook></applicant><applicant mxw-id="PPAR918994409" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Life Sciences Research Partners VZW</last-name><iid>101009153</iid><address><street>Herestraat 49, bus 913</street><city>3000 Leuven</city><country>BE</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918143030" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>SAINT-REMY JEAN-MARIE</last-name><address><country>BE</country></address></addressbook></inventor><inventor mxw-id="PPAR918169167" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>SAINT-REMY, JEAN-MARIE</last-name></addressbook></inventor><inventor mxw-id="PPAR918987349" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>SAINT-REMY, JEAN-MARIE</last-name><address><street>Rue du Lambais 79</street><city>1390 Grez-Doiceau</city><country>BE</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR918978808" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>De Baere, Ivo</last-name><iid>101385832</iid><address><street>IPLodge Technologielaan 9</street><city>3001 Heverlee</city><country>BE</country></address></addressbook></agent></agents></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS548963960" load-source="docdb">AT</country><country mxw-id="DS548963629" load-source="docdb">BE</country><country mxw-id="DS548852087" load-source="docdb">BG</country><country mxw-id="DS548973579" load-source="docdb">CH</country><country mxw-id="DS548963630" load-source="docdb">CY</country><country mxw-id="DS548826094" load-source="docdb">CZ</country><country mxw-id="DS548965069" load-source="docdb">DE</country><country mxw-id="DS548963631" load-source="docdb">DK</country><country mxw-id="DS548963632" load-source="docdb">EE</country><country mxw-id="DS548880700" load-source="docdb">ES</country><country mxw-id="DS548852088" load-source="docdb">FI</country><country mxw-id="DS548852089" load-source="docdb">FR</country><country mxw-id="DS548965074" load-source="docdb">GB</country><country mxw-id="DS548963633" load-source="docdb">GR</country><country mxw-id="DS548826095" load-source="docdb">HU</country><country mxw-id="DS548973581" load-source="docdb">IE</country><country mxw-id="DS548963634" load-source="docdb">IS</country><country mxw-id="DS548852090" load-source="docdb">IT</country><country mxw-id="DS548963635" load-source="docdb">LI</country><country mxw-id="DS548852091" load-source="docdb">LT</country><country mxw-id="DS548963961" load-source="docdb">LU</country><country mxw-id="DS548852092" load-source="docdb">LV</country><country mxw-id="DS548852093" load-source="docdb">MC</country><country mxw-id="DS548963966" load-source="docdb">MT</country><country mxw-id="DS548852094" load-source="docdb">NL</country><country mxw-id="DS548852095" load-source="docdb">PL</country><country mxw-id="DS548880701" load-source="docdb">PT</country><country mxw-id="DS548965075" load-source="docdb">RO</country><country mxw-id="DS548852097" load-source="docdb">SE</country><country mxw-id="DS548971310" load-source="docdb">SI</country><country mxw-id="DS548973582" load-source="docdb">SK</country><country mxw-id="DS548963637" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>AL</country></ep-extended-state-data><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>HR</country></ep-extended-state-data><ep-extended-state-data><country>MK</country></ep-extended-state-data><ep-extended-state-data><country>RS</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data></bibliographic-data><abstract mxw-id="PA128671575" lang="EN" load-source="patent-office"><p id="pa01" num="0001">The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides. The present invention also provides for compositions comprising said peptides.
<img id="iaf01" file="imgaf001.tif" wi="78" he="87" img-content="drawing" img-format="tif"/></p></abstract><search-report-data><doc-page id="srep0001" file="srep0001.tif" wi="161" he="233" type="tif"/><doc-page id="srep0002" file="srep0002.tif" wi="161" he="233" type="tif"/><doc-page id="srep0003" file="srep0003.tif" wi="163" he="233" type="tif"/><doc-page id="srep0004" file="srep0004.tif" wi="157" he="233" type="tif"/><doc-page id="srep0005" file="srep0005.tif" wi="161" he="233" type="tif"/><doc-page id="srep0006" file="srep0006.tif" wi="157" he="233" type="tif"/></search-report-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
